Biologics Process Developments has specialized in contract laboratory services in molecular biology, recombinant protein expression and purification, cell culture, bacterial fermentation, frozen cell/material storage, and consulting in biologics process development and scale-up.
Viropro said that this acquisition is being funded entirely in common stock of Viropro. The company is issuing 90,000,000 shares to Intas as payment. The company intends to implement its business model through the merger or acquisition of current facilities in Europe, North America and India.
Viropro is laying forward a global biotech contract research and manufacturing services offer (CRAMS). Biotech CRAMS consists mostly of outsourced research services from major pharmaceutical and biopharmaceutical companies along the clone-to-clinic value chain, conforming to the international regulatory standards such as the USFDA and EMEA.
Dr Rajiv Datar, co-president of Viropo, said: “As stated in our December press release, Viropro, Inc. will become the holding company of operating subsidiaries in Biotech Contract Research and Manufacturing Services (CRAMS); this is both a first step and a milestone for us and is in keeping with our long-term strategy of building a global biotech CRAMS operation.”
Viropro conducts operations through its subsidiary Viropro International, and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company’s main aim is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets.